Wolverine Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Wolverine Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-9,100	Closed	-$1.18M	–	2072
2022 Q4	$1.18M	Hold	9,100	–	–	0.01%	703
2022 Q3	$1M	Buy	+9,100	New	+$917K	0.01%	785
2021 Q1	–	Sell	-3,300	Closed	-$562K	–	2256
2020 Q4	$562K	Buy	+3,300	New	+$489K	﹤0.01%	811
2019 Q3	–	Sell	-6,100	Closed	-$926K	–	1614
2019 Q2	$926K	Hold	6,100	–	–	0.01%	690
2019 Q1	$727K	Buy	+6,100	New	+$784K	0.01%	752
2018 Q1	–	Sell	-10,000	Closed	-$556K	–	1659
2017 Q4	$556K	Sell	10,000 -3,200	-24%	-$170K	0.01%	878
2017 Q3	$598K	Buy	+13,200	New	+$528K	0.01%	794
2017 Q2	–	Sell	-41,100	Closed	-$1.22M	–	1442
2017 Q1	$1.22M	Buy	+41,100	New	+$1.27M	0.02%	488
2013 Q4	–	Sell	-21	Closed	-$5K	–	2920
2013 Q3	$5K	Buy	+21	New	+$809	﹤0.01%	2394

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Wolverine Asset Management's SRPT Position: Q2 2026 in Review

Wolverine Asset Management held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 4,920 shares worth $88.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1183.

Wolverine Asset Management first reported a position in SRPT in Q4 2013 and has held it in 14 quarters since. The position peaked at $805K in Q1 2014. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Wolverine Asset Management held 4,920 shares of Sarepta Therapeutics worth $88.4K as of Q2 2026.
Wolverine Asset Management left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of Wolverine Asset Management's portfolio in Q2 2026, its #1183 holding.
Wolverine Asset Management first reported a position in Sarepta Therapeutics in Q4 2013 and has held it in 14 quarters since.
Wolverine Asset Management's Sarepta Therapeutics position peaked at $805K in Q1 2014.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Wolverine Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.